eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | myelodysplastic syndrome |
| Symptom | C0002893|refractory anemia |
| Sentences | 11 |
| PubMedID- 20037898 | The findings were diagnostic of myelodysplastic syndrome with refractory anemia with excess of blasts in accordance with the world health organization criteria modified for pediatric age group. |
| PubMedID- 20569983 | We performed an open-labeled single-arm prospective phase ii clinical trial of vitamin k(2) (menatetrenone: vk2) monotherapy and vk2 plus 1alpha-hydroxyvitamin d(3) (alfacalcidol: vd3) combination therapy for myelodysplastic syndromes (mds) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the ipss. |
| PubMedID- 24958999 | The goal of this study was to explore the plasma proteome of myelodysplastic syndrome (mds) patients with refractory anemia with excess blasts subtype 2 (raeb-2) in comparison to healthy controls. |
| PubMedID- 25428262 | The splicing factor sf3b1 is the most commonly mutated gene in the myelodysplastic syndrome (mds), particularly in patients with refractory anemia with ring sideroblasts (rars). |
| PubMedID- 23897263 | Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the fab classification. |
| PubMedID- 20052416 | When we examined chk1 expression in this data set, we found it significantly decreased in patients suffering from myelodysplastic syndromes with refractory anemia with blasts (figure 7b). |
| PubMedID- 24716056 | Final diagnosis was high-grade myelodysplastic syndrome consistent with refractory anemia with excess blasts. |
| PubMedID- 20809214 | Epo+gcsf combination therapy has proven useful in the treatment of patients with refractory anemia due to myelodysplastic syndrome by a synergistic inhibition of progenitor cell apoptosis, and possibly by enhancement of stem cell mobilization . |
| PubMedID- 21434945 | In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. |
| PubMedID- 26171179 | The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome. |
| PubMedID- 21226301 | An 85-year-old woman, who had been given a diagnosis of myelodysplastic syndrome with refractory anemia 2 years previously and required blood transfusion once a month, was admitted with complaints of fever, general fatigue, and dry cough. |
Page: 1